News | Artificial Intelligence | August 11, 2022

AI to Shape Future Outcomes in Cardiovascular Care

Cardiovascular device AI deals hit an all-time high in 2021, totaling nearly $1.6 billion.

Getty Images


August 11, 2022 — The recent deals and collaborations in the medical device space indicate a growing interest in artificial intelligence (AI) applications for the diagnosis and treatment of cardiovascular disease, observes GlobalData, a leading data and analytics company. 

New York-based digital health company Cleerly had raised $192 million in a Series C financing round for its AI-driven diagnostic platform for coronary atherosclerosis in July. Earlier in the month, AI-driven company anumana, inc partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease. 

Jacob Fletcher, MSc, Medical Analyst at GlobalData, comments: “AI is offering cardiologists a new set of tools to aid in decision-making, maximize workflow efficiency, and deliver more personalized patient care. To date, it has been used to predict cardiovascular disease risk, interpret ECGs and diagnostic images, and inform treatment selection. The applications for AI in cardiology have expanded significantly in recent years and was the focal point of several deals and partnerships in July.” 

Last month, researchers from Cornell University announced the launch of the Cardiovascular AI Initiative, a three-year, $15 million collaboration with the New York Presbyterian Hospital to employ AI and machine-learning techniques to inform heart failure treatment and prevention strategies. 

According to GlobalData’s Deals Database, there have been 151 deals involving AI in the cardiovascular devices market since 2020. Cardiovascular device AI deals hit an all-time high in 2021, totaling nearly $1.6 billion. 

Fletcher concludes: “The continued investment in the development of AI-based cardiology tools reflects the growing potential of AI for manufacturers and cardiologists. Significant research efforts will be needed to support its adoption into practice, as patient benefits will need to be clearly demonstrated.” 

For more information: www.globaldata.com 


Related Content

News | ECG

September 29, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG ...

Home September 29, 2022
Home
News | ECG

August 17, 2022 — A new research paper was published in Aging (“Aging (Albany NY)” by Medline/PubMed, “Aging-US” by Web ...

Home August 17, 2022
Home
News | ECG

April 12, 2022 – Biotricity, a medical diagnostic and consumer healthcare technology company, will officially launch the ...

Home April 12, 2022
Home
News | ECG

April 4, 2022 – GE Healthcare and AliveCor have announced a partnership to deliver medical-grade six-lead ...

Home April 04, 2022
Home
News | ECG
February 14, 2022 – MediLynx Cardiac Monitoring, LLC (dba MediLynx Arrhythmia Diagnostics), a national remote monitoring ...
Home February 14, 2022
Home
News | ECG
February 11, 2022 – Philips, a global leader in health technology, announced the introduction of the industry’s first ...
Home February 11, 2022
Home
News | ECG

September 1, 2021 — University of South Australia researchers have designed a computer vision system that can ...

Home September 01, 2021
Home
News | ECG

June 18, 2021 — You might be older ― or younger ― than you think. A new study found that differences between a person's ...

Home June 18, 2021
Home
News | ECG

February 16, 2021 — QT Medical recently announced the launch of Xpress ECG service, the world’s first 12-lead ECG home ...

Home February 16, 2021
Home
News | ECG

February 2, 2021 — Cardiac Insight, Inc. a healthcare company specializing in wearable cardiac sensors and automated ...

Home February 02, 2021
Home
Subscribe Now